Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 205,629,567 papers from all fields of science
Search
Sign In
Create Free Account
EGFR Inhibitor HM61713
Known as:
HM61713
An orally available small molecule, mutant-selective inhibitor of epidermal growth factor receptor (EGFR) with potential antineoplastic activity…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
1 relation
Receptor Tyrosine Kinase Inhibition
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Review
2019
Review
2019
Novel Third-Generation EGFR Tyrosine Kinase Inhibitors and Strategies to Overcome Therapeutic Resistance in Lung Cancer.
A. Murtuza
,
A. Bulbul
,
+5 authors
H. Husain
Cancer research
2019
Corpus ID: 73439605
EGFR-activating mutations are observed in approximately 15% to 20% of patients with non-small cell lung cancer. Tyrosine kinase…
Expand
Review
2017
Review
2017
Recent updates on third generation EGFR inhibitors and emergence of fourth generation EGFR inhibitors to combat C797S resistance.
H. Patel
,
R. Pawara
,
A. Ansari
,
S. Surana
European journal of medicinal chemistry
2017
Corpus ID: 46205661
Review
2016
Review
2016
Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer
Shuhang Wang
,
S. Cang
,
Delong Liu
Journal of Hematology & Oncology
2016
Corpus ID: 2475921
The tyrosine kinase inhibitors (TKI) against epidermal growth factor receptor (EGFR) are widely used in patients with non-small…
Expand
Review
2016
Review
2016
Next-generation epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor -mutant non-small cell lung cancer.
C. Tan
,
B. Cho
,
R. Soo
Lung cancer
2016
Corpus ID: 10685250
Highly Cited
2016
Highly Cited
2016
Acquired C797S Mutation upon Treatment with a T790M-Specific Third-Generation EGFR Inhibitor (HM61713) in Non-Small Cell Lung Cancer.
Haa-Na Song
,
K. S. Jung
,
+11 authors
M. Ahn
Journal of thoracic oncology : official…
2016
Corpus ID: 2007830
2016
2016
BI 1482694 (HM61713), an EGFR mutant-specific inhibitor, in T790M+ NSCLC: Efficacy and safety at the RP2D.
Keunchil Park
,
J. S. Lee
,
+17 authors
Dong-Wan Kim
2016
Corpus ID: 81918132
9055Background: T790M mediates acquired resistance to 1st/2nd generation EGFR-TKIs. BI 1482694 is a 3rd generation TKI active…
Expand
Highly Cited
2015
Highly Cited
2015
Updated safety and efficacy results from phase I/II study of HM61713 in patients (pts) with EGFR mutation positive non-small cell lung cancer (NSCLC) who failed previous EGFR-tyrosine kinase…
Keunchil Park
,
J. S. Lee
,
+16 authors
Dong-Wan Kim
2015
Corpus ID: 74353686
8084 Background: HM61713 is an orally available EGFR mutation-specific inhibitor with sparing EGFR WT tumors that previously…
Expand
Review
2014
Review
2014
Oral epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer: comparative pharmacokinetics and drug-drug interactions.
S. Peters
,
S. Zimmermann
,
A. Adjei
Cancer treatment reviews
2014
Corpus ID: 742714
Highly Cited
2014
Highly Cited
2014
Clinical activity and safety of HM61713, an EGFR-mutant selective inhibitor, in advanced non-small cell lung cancer (NSCLC) patients (pts) with EGFR mutations who had received EGFR tyrosine kinase…
Dong-Wan Kim
,
Dae-Ho Lee
,
+7 authors
J. H. Kim
2014
Corpus ID: 78020433
8011 Background: HM61713 is a novel, oral, selective inhibitor for EGFR mutations including both activating mutations and T790M…
Expand
2014
2014
Abstract LB-100: Discovery of HM61713 as an orally available and mutant EGFR selective inhibitor
Kwang-Ok Lee
,
M. Cha
,
+6 authors
J. Son
2014
Corpus ID: 53766058
Introduction: Activating mutations of EGFR are well known as oncogenic driver mutations in lung adenocarcinoma. Currently, EGFR…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
,
Terms of Service
, and
Dataset License
ACCEPT & CONTINUE